新型B细胞淋巴瘤-2抑制剂——lisaftoclax

A novel inhibitor of B-cell lymphoma-2:lisaftoclax

慢性淋巴细胞白血病(CLL)和小淋巴细胞淋巴瘤(SLL)是常见的血液肿瘤疾病。B细胞淋巴瘤-2(Bcl-2)是一种在血液肿瘤中高表达的关键细胞凋亡调节蛋白,lisaftoclax是一种Bcl-2抑制剂。在前期的临床试验中,lisaftoclax表现出良好的疗效和安全性,即使在1200 mg剂量下也未发生剂量限制性毒性。目前该药物正处于Ⅲ期临床试验的招募阶段。本文对该药物的基本信息、作用机制、药动学、有效性和安全性等方面进行概述。

Chronic lymphocytic leukaemia(CLL)and small lymphocytic lymphoma(SLL)are common haematological tumour diseases.Lisaftoclax is an inhibitor of B-cell lymphoma-2(Bcl-2),a key apoptosis-regulating protein that is highly expressed in haematological malignancies.In early clinical trials,lisaftoclax demonstrated promising efficacy and safety,with no dose-limiting toxicity observed even at 1200 mg.The drug is currently in the recruitment phase of a phaseⅢclinical trial.This article provides an overview of the basic information,mechanism of action,pharmacokinetics,efficacy,and safety of the drug.